CVBF has significant experience as a coordinator of several international projects and participates as a partner in many research projects funded by the European Commission.

CVBF is always proactive in fostering collaboration and interaction with many scientific, clinical and policy stakeholders, facilitating the transfer of know-how achieved at different levels and leading to a strengthening of scientific excellence.

Thanks to its long-lasting experience in projects and initiatives CVBF enhanced networks of relevant stakeholders and collaborative partnerships.

Projects and initiatives

European Joint Programme on Rare Diseases

The Special IssueCVBF Active Involvement in the EJP RD, brief and extended versions, are available here.

The main objective of the European Joint Programme on Rare Diseases (EJP RD) is to create a research and innovation pipeline “from bench to bedside” ensuring rapid translation of research results into clinical applications and uptake in healthcare for the benefit of patients.

In addition, the programme is aimed to improve integration, efficacy, production and social impact of research on rare diseases through the development and promotion of sharing of research and clinical data, materials, processes, knowledge and know-how, and through an efficient model of financial support for research on rare diseases. The number of participating countries is 35 including 27 EU Member States (Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Croatia, Ireland, Italy, Netherlands, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Spain, Sweden, Slovakia, Slovenia, United Kingdom), 7 Associated Countries (Armenia, Georgia, Switzerland, Israel, Turkey, Norway, Serbia) and 1 non-EU Country (Canada). So far, the project brings over 130 institutions including research-funding organization, ERNs (European Reference Networks), European research infrastructures.

The programme is divided into four main Pillars: Funding of research, Coordinated Access to data and resources, Capacity Building, Accelerated translation of research projects and improvement outcomes of clinical studies. Moreover, the following transversal activities are foreseen by the programme within Pillar 0: Integrative Research Strategy, Communication, Sustainability, Ethical, legal, regulatory and IPR issues.

The project sees the participation of CVBF that brings the paediatric competences and expertise within work package 19 aimed to support the Rare Diseases (RD) community to more effectively translate high quality research into high impact interventions for the RD patient community, by creating a bridge between basic research and medical innovation, otherwise known as the “bench to bed-side” approach. To this aim, self-help resources and active project mentoring and technical support is provided to selected projects and CVBF contribute to provide paediatric self-help resources paying particular attention on paediatric projects to be assessed and supported within these activities.

Moreover, CVBF is involved in the monitoring process aimed  to  evaluate the quality of the EJP RD activities and the achievement of the expected project goals during the hole duration of the project  based on the periodic analysis of  proper indicators such as Key Performance Indicators (KPIs) and Key Result Indicators (KRIs).

Find out more in the EJP RD website.

CVBF activities in EJP RD

Creation of the Innovation Management Toolbox, a virtual library to provide self-help resources that is openly accessible to the RD research community, to be utilised by the WP partners and Innovation Managers to implement documents and guidance for projects supported within the EJPDR project itself.  The toolbox includes technical guidance (such as target validation techniques, use of molecular imaging for drug development, patient confidentiality and data handling, animal welfare, biorepositories, plus intellectual property management and contract templates), a project management manual, and regulatory guidance. Particular attention to regulation and resources to promote translational research in the paediatric field is given by CVBF.

Find out more about the IMT here.

c4c – Collaborative network for European clinical trials for children

The “conect4children” (c4c), an IMI-2 project, is composed of 43 industrial and non-industrial partners with the aim to deliver high quality clinical trials in children and young people across all conditions and phases.

The c4c consortium aims to enhance the competitiveness of Europe as a critical region for developing medicines for children by using existing expertise, patient access and developing common processes to be applied to disease natural history studies, registries, studies of new therapies and comparisons of existing therapies.

The consortium is a novel collaboration between academic and private sectors that includes 33 academic and 10 industry partners from 20 European countries, more than 50 third parties and around 500 affiliated partners.

The six-year project, comprised of a multidisciplinary public-private consortium, brings together key stakeholders across academia and industry. It is a pioneering opportunity to build capacity for the management of multinational paediatric clinical trials across Europe whilst ensuring the voices of children, young people and their families are heard. Strong links with regulators will be established.

CVBF is involved in the WP5 “Data coordinating centre and data quality standards” and has a relevant role in the delivery of training and education within c4c network being involved in the WP6 “Network Re­search Personnel Education and Training” as well as in the communication activities of the WP8 “Commu­nication, Dissemination, Exploitation and Impact Assessment”.

Finally, CVBF is member of the Cross-cutting theme in charge of the patients’ involvement in the project.

Find out more in the project website

EPTRI – European Paediatric Translational Research Infrastructure

EPTRI is a new research infrastructure with the aim to speed up and promote the paediatric research in the field of discovery and development of paediatric drugs focusing on basic, preclinical, and translational research in the field of drug discovery, paediatric biomarkers and biosamples, developmental pharmacology, paediatric medicines formulations, medical devices and advanced therapies.

EPTRI has just entered in the Preparatory phase to reach its legal, financial and technical maturity, and is composed of more than 100 Institutions from 25 Countries, organising themselves in National Nodes and acting as service providers.

EPTRI is following its process of creation of the EPTRI-ERIC that will take some time. Meanwhile, to be able to undertake several actions as a legal entity, such as to participate in EU funded calls, apply for inclusion in public-private partnerships, Associations and Networks, it is creating an international non-profit organization under the Belgium law, called AISBL – Association internationale sans but lucrative.

EPTRI will provide three types of services:

  • Centralised services, which are: access to Document Repository and e-Libraries, scientific advice on preclinical and translational research, advice on translation to clinical phases, service for scouting of research funding opportunities, training and education;
  • Integrated services, provided by the research units and managed within the Thematic Research Platforms;
  • Common services, in collaboration with other biomedical RIs (to be defined).

EPTRI will bring a positive impact on the scientific community, by integrating the different research units within the new establishing RI, so to increase the scientific relevance of the paediatric research at international level.

EPTRI will bring together scientists, researchers, regulators, and industry to support smarter paediatric medicines development in an atmosphere of innovation and collaboration for the benefit of the patients, the life science, the economy and ultimately the society. It will also benefit children’s and future generations’ health as it will establish the framework to speed-up the drug development process in paediatrics including the top-level research innovations.


The Paediatric Clinical Research Infrastructure Network (PedCRIN) is a EU-funded project aimed to bring together the European Clinical Research Infrastructure Network (ECRIN) and the founding partners of the European Paediatric Clinical Trial Research Infrastructure (EPCT-RI) to develop capacity for the management of multinational paediatric clinical trials.

It arises from the awareness that more clinical trials are required to address specific needs of the paediatric population. Children do not often receive appropriate treatments since many medicinal products have not been adequately tested or authorised for them. Moreover, the paediatric population often responds to drugs and other therapeutics differently than adults do.

There are several scientific and operational challenges for conducting paediatric clinical trials. Additionally, non-commercial trials have to face many difficulties, e.g. lack of funding, inadequate infrastructure and lack of platform to facilitate collaboration and discussion.

The aim of PedCRIN is, therefore, to develop the necessary tools and capacity to enhance the quality, safety, efficacy and ethical standards of multinational, non-commercial paediatric clinical trials.

CVBF, as partner in collaboration with the TEDDY Network, will be responsible for the creation of tools specific for paediatric trials or for the upgrade of tools and databases, already developed by ECRIN for adult trials, to take into consideration paediatric specificities.

One of the main initiatives of the project is the launching of a call supporting the multinational extension of paediatric studies on medicinal products having already secured funding in the coordinating country and to select, based on scientific excellence and evidence for feasibility, multi-national investigator-initiated paediatric or neonatal interventional clinical studies on medicinal products.

More information on PedCRIN are available in the project factsheet and in the project website.

CloSed – Clonidine for Sedation of Paediatric Patients in the Intensive Care Unit

CloSed was a 5-year project funded under the Seventh Framework Programme (FP7) with an international Consortium comprising 10 European partners and coordinated by Assoc. Prof. Antje Neubert, University Hospital of Erlangen (UKER).

The project aimed to perform a multicentre and multinational paediatric clinical trial studying clonidine, a drug already used for sedation in Pediatric Intensive Care Units (PICUs) but not authorised in paediatric population. The ultimate goal is to make a parenteral age-appropriate formulation of clonidine available on the market for sedation in PICUs and to apply for a Paediatric Use Marketing Authorisation (PUMA). Furthermore, the CloSed project partners will use the findings of the clinical trial to develop and disseminate European consensus guidelines for sedation in critically ill newborns and children which will support all clinicians across Europe in their decisions.

CVBF was involved in the CloSed project as FGB (Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus) Third Party and is in charge of Pharmacovigilance activities.

Closed logo

DEEP – DEferiprone Evaluation in Paediatrics

DEEP was a project funded by the Seventh Framework Programme of the European Commission, with the purpose to develop a new oral liquid formulation, suitable for children, of deferiprone (DFP) for the treatment of iron overload in paediatric patients affected by congenital anaemias, such as β-thalassaemia major (the so called “Mediterranean anaemia”) and sickle-cell disease (SCD), that require chronic transfusion therapy.

The Project included three studies aimed to evaluate the pharmacokinetics (DEEP-1 study), efficacy/safety (DEEP-2 study) and long-term safety (DEEP-3 study) of deferiprone in this specific patient population, in accordance with the Paediatric Investigation Plan (PIP) approved by the EMA Paediatric Committee (PDCO).

The DEEP Project provided the scientific evidence that the dosage per kilogram of DFP used in adults and older children can provide sufficient exposure to ensure efficacy also in younger children (DEEP-1 PK clinical trial that involved 21 patients under 6 years).

These results allowed children under the age of 6 years to be recruited in the safety/efficacy study (DEEP-2) that involved a total of 393 patients with the first patient first visit (FPFV) held in March 2014 and the last patient last visit (LPLV) in September 2017. This is the largest randomised trial in children with transfusion-dependent hemoglobinopathies comparing two oral chelating agents (deferiprone vs deferasirox) conducted so far, providing evidence to support the use of DFP in paediatric patients.

In addition, through the long-term observational safety study (DEEP-3) the nature and incidence of adverse effects of deferiprone in children and adolescents was evaluated. Started in 2013 and ended in October 2015, with 297 patients enrolled in the study, DEEP-3 confirmed that the safety profile of DFP in children and adolescents is in accordance with the available data in adults.

On the basis of the above-mentioned findings, a Paediatric Use Marketing Authorisation (PUMA) for the new formulation of deferiprone has been submitted by the commercial partner of the project (ApoPharma Inc., which also provided financial support for the continuation of the project).

During the project particular attention has been payed to the development of age-tailored informative tools addressed to the children involved in the studies.

Find out more in the project website.

GAPP – GAbapentin in Paediatric Pain

The GAPP (GAbapentin in Paediatric Pain) project, funded by the Seventh Framework Programme of the European Commission, was intended to improve the therapeutic perspectives of children who suffer from chronic pain, providing them with a drug, gabapentin, which seems to be effective and safe, as already demonstrated in adults, and which was included in the European priority list of off-patent paediatric medicines worthy of research grants.

A comprehensive development strategy has been put in place including a new paediatric formulation, a non-clinical study and two clinical trials. Such strategy was agreed with the Paediatric Committee (PDCO) at the EMA in January 2013 and in July the GAPP Project officially started. During the course of the project a new formulation was developed, a juvenile preclinical study was conducted and the two clinical studies were formally activated in all recruiting centers. In July 2017, the project officially terminated, but the trials were not yet concluded. Due to the strong interest and commitment of the Parties, and in particular of the studies’ Sponsor (PHARM srl), it was decided to take over the continuation of the GAPP studies through a fund raising.

At the end of the project and on the basis of the study results, an application for a Paediatric Use Marketing Authorisation (PUMA) for the treatment of chronic pain in children both as monotherapy and as adjuvant therapy will be submitted by the commercial partner of the approved Project.

Find out more on the project website.

GAPP logo

EPIICAL – Early treated Perinatally HIV Infected individuals: Improving Children’s Actual Life

EPIICAL was a 4-years (2016-2020) project funded by ViiV Healthcare U.K. (ViiV), and aimed to evaluate strategies to optimise the management of perinatally HIV-infected children and to establish a predictive in vitro and in vivo platform to inform treatment strategies leading to HIV remission. The treatment strategies may include combination antiretroviral therapy (cART) as well as Novel Disease Modifying Therapies (NDMTs). These goals will be achieved through the creation of an innovative research platform developed from in vitro and in vivo proof of concept studies using the model of early treated HIV-infected children population. To validate this predictive platform, new immunological, virological and transcriptomic profiles of viral control in children will be generated with data obtained from well-established cohorts/studies of early treated HIV-infected children around the world (both observational cohorts and clinical trials cohorts). Within the project framework, through its member Gianni Benzi Pharmacological Research Foundation, CVBF provides support in managing ethical, regulatory and legal issues on the secondary use of data and samples and is in charge of the preparation of submission packages for EPIICAL proof of concept study, as required by applicable international/European/national laws.

Find out more in the project website.

ID-EPTRI – European Paediatric Translational Research Infrastructure

The ID-EPTRI (European Paediatric Translational Research Infrastructure) project, coordinated by CVBF, was funded by the European Commission under the INFRADEV-01 call with the aim to design the framework for a new Research Infrastructure (RI) aimed to enhance technology-driven paediatric research in drug discovery and early development phases to be translated into clinical research and paediatric use of medicines.

The starting point of the project was the serious lack of medicines for children in EU and worldwide as well as the lack of a developmental model for paediatric medicines that integrates technology-driven aspects with the methodological, ethical and regulatory framework.

The ID-EPTRI project involved 29 partners from 21 EU and non-EU countries, including established RIs, non-profit research organisations, top-level universities, scientific and clinical centers of excellence.

During the ID-EPTRI project (2018-2020), the EPTRI concept has been designed and tested and has allowed to create the base for research excellence that is the added value of the EPTRI proposal. The scientific concept of EPTRI was tested and found feasible through different actions: a) the scientific community survey (259 respondents and more than 300 research units identified); b) the users survey (337 respondents from clinical researcher centres, regulatory, industry, other researchers; c) the scientific feasibility studies including 10 studies with scientists; d) the stakeholders consultation; e) the Governments consultation;  e) the final virtual stakeholders’ roundtable on July 9th, 2020 to present the final outcomes of the EPTRI design phase and to discuss its feasibility.

EPTRI has been designed as a distributed RI according to a Hub and Spoke model, with a Central Management Office (CMO), a Single Access Point (SAP) interconnected with specific Thematic Research Platforms and several National Nodes.

The following four TRPs have been created grouping RUs in each specific scientific domain and able to act as providers of cutting-edge services that are unique for paediatric research on medicines setting:

  • PAEDIATRIC MEDICINES DISCOVERY dedicated to basic research and preclinical studies to identify molecular targets to paediatric disease on models reproducing specific paediatric ontogenetic stages;
  • PAEDIATRIC BIOMARKERS AND BIOSAMPLES focused on the organisation of paediatric samples collection and the identification, characterisation and validation of paediatric biomarkers;
  • DEVELOPMENTAL PHARMACOLOGY devoted to the identification and application of ad hoc innovative methods to study paediatric pharmacological variability due to ontogeny;
  • PAEDIATRIC MEDICINES FORMULATIONS devoted to performing pre-formulation and formulation studies from preterm neonates to adolescents.

Visit the project website